FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159492062> ?p ?o ?g. }

• W3159492062 endingPage "2492" @default.
• W3159492062 startingPage "2492" @default.
• W3159492062 abstract "Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the production of β2-glycoprotein I (β2GPI)-dependent autoantibodies, with vascular thrombosis or obstetrical complications. Around 20% of APS patients are refractory to current treatments. Crassolide, a cembranoid diterpene extracted from soft corals, is a potential therapeutic candidate. Here, to examine the anti-inflammatory properties of crassolide, we first determined its effects on bone marrow-derived and splenic dendritic cells (DC). Specifically, we applied lipopolysaccharide (LPS) or β2GPI stimulation and measured the expressions of CD80 and CD86, and secretions of cytokines. We also determined in the OT-II mice, if bone marrow-derived DC was able to stimulate antigen-specific T cells. Moreover, we examined the therapeutic potential of crassolide postimmunization in a murine model of APS that depended on active immunization with β2GPI. The vascular manifestations were evaluated in terms of fluorescein-induced thrombi in mesenteric microvessels, whereas the obstetric manifestations were evaluated based on the proportion of fetal loss after pregnancy. We also measured blood titers of anti-β2GPI antibody, splenic cell proliferative responses and cytokine secretions after β2GPI stimulation ex vivo. Finally, we determined in these mice, hematological, hepatic and renal toxicities of crassolide. Crassolide after LPS stimulation suppressed DC maturation and secretion of tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-12 and IL-23, and downstream T cell activation. Crassolide could partially ameliorate both the vascular and obstetric manifestations of APS in BALB/c mice. Both blood titers of anti-β2GPI antibody and splenic cell proliferation after β2GPI stimulation were reduced. Splenic Th1 and Th17 responses were also lowered after β2GPI stimulation. Finally, within therapeutic doses of crassolide, we found no evidence of its toxicity. In conclusion, we showed the ability of crassolide to suppress DC and downstream T cell responses. Crassolide is therefore a potential candidate for adjunctive therapy in APS." @default.
• W3159492062 created "2021-05-10" @default.
• W3159492062 creator A5010239816 @default.
• W3159492062 creator A5010630115 @default.
• W3159492062 creator A5046105082 @default.
• W3159492062 creator A5053254960 @default.
• W3159492062 creator A5078271785 @default.
• W3159492062 creator A5079145162 @default.
• W3159492062 date "2021-04-24" @default.
• W3159492062 modified "2023-10-15" @default.
• W3159492062 title "Crassolide Suppresses Dendritic Cell Maturation and Attenuates Experimental Antiphospholipid Syndrome" @default.
• W3159492062 cites W1979695362 @default.
• W3159492062 cites W1984767455 @default.
• W3159492062 cites W1996136378 @default.
• W3159492062 cites W2000558721 @default.
• W3159492062 cites W2009845069 @default.
• W3159492062 cites W2023929943 @default.
• W3159492062 cites W2028959870 @default.
• W3159492062 cites W2030947987 @default.
• W3159492062 cites W2050293393 @default.
• W3159492062 cites W2052925499 @default.
• W3159492062 cites W2053081517 @default.
• W3159492062 cites W2059791701 @default.
• W3159492062 cites W2060057918 @default.
• W3159492062 cites W2060742488 @default.
• W3159492062 cites W2065435424 @default.
• W3159492062 cites W2067055769 @default.
• W3159492062 cites W2071969437 @default.
• W3159492062 cites W2074744674 @default.
• W3159492062 cites W2092125033 @default.
• W3159492062 cites W2094539145 @default.
• W3159492062 cites W2096729648 @default.
• W3159492062 cites W2143744274 @default.
• W3159492062 cites W2155997720 @default.
• W3159492062 cites W2160198109 @default.
• W3159492062 cites W2160628887 @default.
• W3159492062 cites W2340670419 @default.
• W3159492062 cites W2398878424 @default.
• W3159492062 cites W2410380589 @default.
• W3159492062 cites W2594879804 @default.
• W3159492062 cites W2604881846 @default.
• W3159492062 cites W2754891609 @default.
• W3159492062 cites W2756468099 @default.
• W3159492062 cites W2766106917 @default.
• W3159492062 cites W2791629902 @default.
• W3159492062 cites W2807995133 @default.
• W3159492062 cites W2808036431 @default.
• W3159492062 cites W2887652741 @default.
• W3159492062 cites W2887907495 @default.
• W3159492062 cites W2894608536 @default.
• W3159492062 cites W2915515594 @default.
• W3159492062 doi "https://doi.org/10.3390/molecules26092492" @default.
• W3159492062 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8123116" @default.
• W3159492062 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33923336" @default.
• W3159492062 hasPublicationYear "2021" @default.
• W3159492062 type Work @default.
• W3159492062 sameAs 3159492062 @default.
• W3159492062 citedByCount "6" @default.
• W3159492062 countsByYear W31594920622021 @default.
• W3159492062 countsByYear W31594920622022 @default.
• W3159492062 countsByYear W31594920622023 @default.
• W3159492062 crossrefType "journal-article" @default.
• W3159492062 hasAuthorship W3159492062A5010239816 @default.
• W3159492062 hasAuthorship W3159492062A5010630115 @default.
• W3159492062 hasAuthorship W3159492062A5046105082 @default.
• W3159492062 hasAuthorship W3159492062A5053254960 @default.
• W3159492062 hasAuthorship W3159492062A5078271785 @default.
• W3159492062 hasAuthorship W3159492062A5079145162 @default.
• W3159492062 hasBestOaLocation W31594920621 @default.
• W3159492062 hasConcept C154317977 @default.
• W3159492062 hasConcept C159654299 @default.
• W3159492062 hasConcept C17991360 @default.
• W3159492062 hasConcept C202751555 @default.
• W3159492062 hasConcept C203014093 @default.
• W3159492062 hasConcept C2776090121 @default.
• W3159492062 hasConcept C2776874634 @default.
• W3159492062 hasConcept C2778297628 @default.
• W3159492062 hasConcept C2778690821 @default.
• W3159492062 hasConcept C2780007613 @default.
• W3159492062 hasConcept C2780931953 @default.
• W3159492062 hasConcept C2781101188 @default.
• W3159492062 hasConcept C39347974 @default.
• W3159492062 hasConcept C55493867 @default.
• W3159492062 hasConcept C71924100 @default.
• W3159492062 hasConcept C86803240 @default.
• W3159492062 hasConcept C8891405 @default.
• W3159492062 hasConceptScore W3159492062C154317977 @default.
• W3159492062 hasConceptScore W3159492062C159654299 @default.
• W3159492062 hasConceptScore W3159492062C17991360 @default.
• W3159492062 hasConceptScore W3159492062C202751555 @default.
• W3159492062 hasConceptScore W3159492062C203014093 @default.
• W3159492062 hasConceptScore W3159492062C2776090121 @default.
• W3159492062 hasConceptScore W3159492062C2776874634 @default.
• W3159492062 hasConceptScore W3159492062C2778297628 @default.
• W3159492062 hasConceptScore W3159492062C2778690821 @default.
• W3159492062 hasConceptScore W3159492062C2780007613 @default.
• W3159492062 hasConceptScore W3159492062C2780931953 @default.
• W3159492062 hasConceptScore W3159492062C2781101188 @default.

• next